Daily Medication Pearl: Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) for Hepatitis C

Vosevi is a fixed-dose combination for the treatment of hepatitis C virus.

Medication Pearl of the Day: Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)

Indication: Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) is a fixed-dose combination for the treatment of hepatitis C virus (HCV). It combines 3 drugs that each act by a different mechanism of action against HCV.

Insight:

  • Dosing:Recommended dosage 1 tablet (400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir) taken orally once daily with food,
  • Dosage forms: Tablets 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.
  • Adverse events:The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with Vosevi for 12 weeks were headache, fatigue, diarrhea, and nausea.
  • Mechanism of action: Vosevi is a fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir, which are direct-acting agents against HCV.
  • Manufacturer: Gilead Pharmaceuticals

Source: LABEL (fda.gov)